1 2	A low pre-existing anti-NS1 humoral immunity to DENV is associated with microcephaly development after gestational ZIKV exposure
3 4 5 6	Sebastián Castro-Trujillo <sup>1</sup> , William R. Mejía <sup>2,3</sup> , Katherine Segura <sup>1,4</sup> , Rocío Vega <sup>2,3</sup> , Doris Salgado <sup>2,3</sup> , Carlos E. Fonseca <sup>3</sup> , Ángela M. Ortiz <sup>2,3</sup> , Federico Perdomo-Celis <sup>4</sup> , Irene Bosch <sup>5</sup> , Carlos F. Narváez <sup>1,2</sup> .
7	
8	1 División de Inmunología, Programa de Medicina, Facultad de Ciencias de la Salud,
9	Universidad Surcolombiana, Neiva 41001, Huila, Colombia.
10 11	2 Área de Pediatría, Departamento de Ciencias Clínicas, Facultad de Ciencias de la Salud, Universidad Surcolombiana Neiva Huila Colombia
17	<ol> <li>Servicio de Pediatría Hospital Universitario de Neiva Neiva Huila Colombia</li> </ol>
13	<ul> <li>4 Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana,</li> </ul>
14	Bogola, Colombia.
15 16	5 Institute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT), Combridge Massachusetts USA
10 17	Camonuge, Massachuseus, OSA.
17 18	
10	Address for correspondence:
20	
21	Carlos F. Narváez, MD, PhD, División de Inmunología, Facultad de Ciencias de la Salud,
22	Universidad Surcolombiana. Calle 9 # 14 – 03, Barrio Altico, Neiva 41001, Huila, Colombia.
23	E-mail: <u>cfnarvaez@usco.edu.co</u>
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	Short title: Relationship between the NS1 humoral response and the congenital Zika syndrome.
34	
35	
36	
37	
38	Keywords: Zika; Dengue; NS1; Microcephaly; IgG; IgM; ELISA.
39 40	

# 41 ABSTRACT

#### 42

**Background:** Gestational Zika virus (ZIKV) infection is associated with the development of congenital Zika syndrome (CZS), which includes microcephaly and fetal demise. The magnitude and quality of orthoflavivirus-specific humoral immunity have been previously linked to the development of CZS. However, the role of ZIKV NS1-specific humoral immunity in mothers and children with prenatal ZIKV exposure and CZS remains undefined. In addition, considering that most of the at-risk population lives in dengue virus (DENV)-endemic areas, it is not clear what is the association between pre-existing DENV NS1-specific humoral immunity and CZS.

50 **Methods:** Here, we studied 328 mothers and children with a clinical diagnosis and seropositivity

51 for ZIKV infection during pregnancy, included during the 2015-2016 ZIKV epidemic in

52 Colombia. We also performed clinical evaluation and pediatric neurological follow-up. The

relative levels of circulating NS1-specific IgM and IgG against ZIKV and DENV were evaluated

54 in mothers and children, and the association with the development of microcephaly was analyzed.

55 Results: DENV and ZIKV IgG-NS1 antibodies in pregnant women were placentally transferred,

and this passage and its duration in children depended on the maternal levels of the antibodies. We

57 reported that higher concentrations of pre-existing DENV, but not ZIKV IgG-NS1 antibodies,

were associated with a reduced risk of CZS-related microcephaly. Also, we observed that the IgM-

59 NS1 response presents as long-term and has a minor association with poor outcomes.

60 Conclusions: The development of microcephaly in children prenatally exposed to ZIKV is 61 associated with low plasma levels of placentally transferred, pre-existing DENV IgG-NS1 62 antibodies. These data are compatible with a protective role of anti-NS1 IgG antibodies against 63 ZIKV infection during pregnancy and highlight the promising role of NS1 as an orthoflavivirus

64 vaccine target in high-risk populations.

65 66

#### 81 INTRODUCTION

Zika Virus (ZIKV) is an arbovirus transmitted to humans through the bite of Aedes mosquitoes 82 [1]. Like other orthoflaviviruses (such as dengue virus [DENV]), ZIKV is an enveloped virus with 83 a positive-sense, single-stranded RNA genome that codifies for three structural proteins (E, preM, 84 and C) and seven nonstructural proteins [2]. Zika virus is a re-emerging pathogen that in 2022 had 85 affected at least 89 countries worldwide, primarily in tropical and subtropical regions [3]. Between 86 October 2015 and July 2016, active autochthonous transmission of ZIKV was confirmed in 87 Colombia, leading to a nationwide epidemic declaration [4]. In February 2016, the World Health 88 Organization (WHO) declared ZIKV infection a public health emergency of international concern 89 90 [3], given the link between ZIKV infection during pregnancy and subsequent birth defects [5]. 91 Indeed, although ZIKV infection is asymptomatic in most cases or courses as a self-limited and mild disease [6], when infection occurs during pregnancy, ZIKV can be vertically transmitted, 92 resulting in spontaneous abortion or the development of congenital Zika syndrome (CZS) [6]. This 93 94 neonatal syndrome includes microcephaly, intracranial calcifications, ophthalmologic abnormalities, and neurodevelopmental disorders [7]. In addition, infants with CZS may have a 95 96 case fatality rate of 10% within the first years of life [8]. In Colombia, microcephaly prevalence increased from 2.1 per 10,000 live births in 2015 to 9.6 in 2016, supporting the association between 97

98 reported ZIKV infections and the occurrence of this clinical entity [9].

99

The mechanisms responsible for the development of CZS are not fully understood. While it is 100 known that ZIKV can infect and induce the death of human neural progenitor cells [10,11], tissue 101 damage may also be associated with an exacerbated immune response triggered by the infection 102 [12–14]. Furthermore, the humoral immune response against ZIKV and pre-existing immunity to 103 orthoflaviviruses may play protective or pathogenic roles in CZS [15]. Indeed, previous studies 104 have shown that neutralizing human antibodies directed to the ZIKV E protein can protect against 105 ZIKV replication and fetal demise in mice [16]. In contrast, pre-existing DENV-specific antibodies 106 107 in mice infected with ZIKV during pregnancy may enhance vertical ZIKV transmission, resulting in microcephaly [17]. It is worth noting that while there has been extensive research on the humoral 108 response to the ZIKV and DENV E proteins, the response to the NS1 protein has not been studied 109 as extensively. This protein is highly immunogenic [18] and is associated with severe disease as 110 well as placental dysfunction [19]. A considerable proportion of the antibodies elicited by ZIKV 111 and DENV are targeted toward NS1 [20-22]. These antibodies exhibit lower cross-reactivity than 112 those directed to the E protein of related orthoflaviviruses, particularly DENV, which makes them 113 a valuable tool in the diagnosis [23]. In addition, anti-ZIKV NS1 antibodies decrease the risk of 114 antibody-dependent enhancement of infection [20,24], highlighting their role in antibody-115 116 mediated protection against disease and as an optimal target in vaccine development. In keeping with these data, previous studies have suggested that anti-ZIKV NS1 antibodies derived from adult 117 samples have a protective role against ZIKV disease [24,25]. Moreover, it was demonstrated that 118 antibodies recognizing cell-surface NS1 confer protection against ZIKV in pregnant mice [26]. 119 However, it is unknown the role of anti-DENV NS1 antibodies in CZS. 120

121

Previous research has examined the link between the cellular immune response in mothers and 122 children and the development of CZS [27,28]. However, the connection between pre-existing 123 humoral immunity in mothers and CZS in their children remains unexplored. Particularly, it is 124 unknown whether anti-ZIKV NS1 humoral immunity in mothers and children with prenatal ZIKV 125 exposure is associated with CZS, especially in severe forms such as microcephaly. In addition, 126 since most of the at-risk population lives in dengue-endemic areas, it is essential to determine the 127 association between pre-existing anti-DENV NS1 antibodies and children and CZS development. 128 To investigate these aspects, we evaluated the levels of anti-NS1 IgM and IgG antibodies against 129 ZIKV and DENV in mothers and their offspring exposed to ZIKV during pregnancy. We observed 130 the transplacental passage of anti-NS1 IgG (but not IgM) antibodies from ZIKV and DENV, with 131 132 an expected clearance rate. In addition, we found a relationship between the levels of pre-existing anti-NS1 humoral immunity to DENV and the occurrence of CZS-related microcephaly. 133

134

#### 135 METHODS

#### 136 Ethics statement

137 The study adhered to the principles of the Declaration of Helsinki and received approval from the 138 Ethics, Bioethics, and Research Committee of the Hospital Universitario Hernando Moncaleano 139 Perdomo in Neiva, Huila, Colombia (No. 004-007, April 19, 2016) and from the Ethics and 140 Research Committee of clínica ESIMED (Minute No. 007 dated September 14, 2016). All 141 participating mothers provided written informed consent for themselves and their children.

142

#### 143 Participants, samples, and pediatric follow-up

A multicenter study was conducted including two independent cohorts with a total of 436 144 participants: the Hospital Universitario Hernando Moncaleano Perdomo cohort (n=272; mothers 145 and children), and the clínica ESIMED cohort (n=164; mothers and children), both located in 146 Neiva, southern Colombia, a hyper-endemic region for dengue [29]. We included mother/child 147 binomials with the antecedent of gestational exposure to ZIKV during the 2015-2016 Zika 148 epidemic. Exposure to ZIKV was defined as the presence of plasma anti-ZIKV NS1 IgG antibodies 149 150 in the mothers, accompanied by signs and symptoms of Zika disease during pregnancy at the peak of the epidemic period. In all cases, TORCH syndrome (Toxoplasmosis, Other infections [such as 151 syphilis and HIV], Rubella, Cytomegalovirus, Herpes simplex) was ruled out by serological or 152 molecular testing. The study inclusion time was 0.2 to 19 months after the child's birth. At 153 enrollment, a blood sample was obtained simultaneously from all mothers and their infants (4 or 154 155 2 mL, respectively, collected in ethylenediaminetetraacetic acid-containing tubes). Plasma was isolated through centrifugation at 200 x g for 5 minutes and stored at -80°C until analysis. 156 Neurological, speech therapy, and ophthalmological assessments were conducted for 113 children 157 up to 12 months after enrollment. The children's cognitive, language, and motor development were 158 evaluated with the Bayley-III child development scale and applied by a pediatric neurologist 159 specialist. Neurodevelopment alteration was defined as <85 points in any of the parameters 160

evaluated [30]. The complete characterization of neurological disturbances in these children can
be found elsewhere [31]. The study chart flow is presented in Figure 1.

163

# 164 Measurement of plasma anti-NS1 IgM and IgG antibodies to ZIKV and DENV

Indirect enzyme-linked immunosorbent assays (ELISA) based on recombinant whole NS1 protein 165 of ZIKV (Surinam strain, No. ZIKV-NS1) and a mix of the four NS1 DENV serotypes (DENV-1 166 Nauru/Western Pacific/1974, DENV-2 Thailand/16681/84, DENV-3 Sri Lanka D3/H/IMTSSA/ 167 SRI/2000/1266 and DENV-4 Dominica/814669/1981) were used to evaluate the relative levels of 168 IgM and IgG antibodies in plasma samples (here referred to as IgG-NS1 or IgM-NS1), as 169 previously reported [32,33]. Samples obtained before 2014 from healthy individuals serologically 170 without exposure to either ZIKV or DENV were used as a negative control. Based on the negative 171 control, a detection limit of 0.27 and 0.36 optical densities (OD 450 nm) was established for anti-172 NS1 IgM and IgG, respectively. Additionally, samples from convalescent patients with confirmed 173 ZIKV or DENV infection were included as a positive control. Anti-NS1 IgM and IgG antibodies 174 are reported as a positivity rate (percent of samples with OD 450 nm above the detection limit) 175 176 and relative levels (raw OD 450 nm values). All samples were evaluated in duplicate. Inter-plate variability in the positive and negative controls was lower than 15%. 177

178

#### 179 Statistical Analysis

Statistical analysis was performed with GraphPad Prism version 10. Quantitative analyses are 180 presented as medians and range. Frequency analyses were done using Fisher's exact test. The 181 Mann-Whitney and Wilcoxon tests were used for unpaired and paired analyses of the two groups, 182 respectively. Three or more independent groups were compared with Kruskal-Wallis and Dunn's 183 post-hoc tests. The correlation between variables was determined using the Spearman rank test. 184 The cutoff of DENV1-4/ZIKV IgG-NS1 ratio to predict microcephaly outcome was evaluated 185 using receiver operating characteristic (ROC) curve analyses. The better cutoff was chosen using 186 187 the Youden J Index (sensitivity + specificity -1). A p-value <0.05 was considered significant. When comparing IgM or IgG values, statistical analysis was performed only if the median level of any 188 group was above the limit of detection of the assay. 189

190

# 191 **RESULTS**

# 192 Characteristics of the study cohort

193 We included 218 mother and child pairs with clinical suspicion of prenatal ZIKV exposure. From

them, 190 had available clinical records and plasma samples. In turn, 164 mothers were positive

195 for IgG-NS1 ZIKV (**Figure 1**). Clinical follow-up was performed in 113 children. From them, 67

cases presented CZS: 17 developed microcephaly, 14 had ocular abnormalities, and 36 exhibited

only neurodevelopmental impairment (Figure 1). In 51 normocephalic infants, clinical follow-up
 could not be performed. The clinical and demographic characteristics of the study cohort are shown

in **Table 1**. We grouped the participants as those without or with microcephaly. We did not observe 199 200 differences in the age of mothers from both groups (Table 1). However, consistent with the link between ZIKV infection during the first trimester of pregnancy and microcephaly [34], in our 201 202 cohort, a higher proportion of cases of microcephaly occurred after ZIKV infection in the first trimester (Table 1). In contrast, most cases of neurodevelopment and ocular alterations, such as 203 optical nerve hypoplasia and chorioretinitis, occurred after ZIKV infection during the second 204 trimester (**Supplementary Table 1**). We did not observe differences in the gestational age at birth, 205 in the clinical manifestations of suspected ZIKV infection in the mothers (including fever, 206 exanthema, and myalgias/arthralgias), and in the biological sex of the infants between those with 207 versus without microcephaly (Table 1). 208

209

# 210 Placental transfer of ZIKV and DENV IgG-NS1 antibodies

The dynamic of the humoral response to ongoing gestational ZIKV infection, as well as pre-211 existing antibodies against DENV, remains unclear. Thus, we evaluated the plasma levels of ZIKV 212 and DENV IgM-NS1 and IgG antibodies in pregnant mothers and their newborns to determine the 213 214 transfer of these antibodies across the placenta and their temporal kinetics. Consistent with the absence of ongoing or recent ZIKV or DENV infection at the time of sample collection, overall, 215 there were low or undetectable levels of IgM-NS1 both in mothers and children (Figure 2A and 216 **B**; Supplementary Figure 1A). This was also reflected in a poor correlation between IgM-NS1 217 in mothers and children (Figure 2A and B). Moreover, consistent with the lack of transplacental 218 passage of IgM [35], in some mothers with detectable levels of DENV IgM-NS1, these values 219 220 were not observed in their children (Figure 2B).

221

In contrast to IgM-NS1, there was a high positivity rate of IgG-NS1, a pattern consistent with the 222 high levels of endemic DENV transmission in this population [29]. As expected, the levels were 223 224 higher in the mothers than in the children (Supplementary Figure 1B). In addition, we observed higher levels of DENV than ZIKV IgG-NS1 in mothers and children (Supplementary Figure 225 **1B**). It is known that placental transport of IgG depends on maternal levels [35]. In keeping with 226 this notion, we observed a positive correlation between IgG-NS1 in mothers and children, but the 227 strength of association was higher for DENV IgG-NS1 (Figure 2C and D). Consistent with the 228 kinetics of clearance of maternally acquired anti-orthoflavivirus IgG [36,37], the levels of ZIKV 229 and DENV IgG-NS1 declined in the infants predominantly from the sixth month of age onward, 230 nearly disappearing by the eighth month (Figure 2E and F). Of note, in children before six months 231 of age, the frequency of undetectable IgG-NS1 was significantly higher for ZIKV than for DENV 232 (69% vs. 30%, p<0.001), indicating that a significant proportion of infants could be susceptible to 233 ZIKV reinfection early after birth. In contrast, the levels of these antibodies remained relatively 234 stable in the mothers (Figure 2E and F). 235

236

We also evaluated the impact of the time of ZIKV exposure on the levels of DENV and ZIKV IgG-NS1. As such, we compared the antibody levels in samples from mothers and children

exposed to ZIKV during the first versus the third trimester of pregnancy. The mothers who were 239 exposed to ZIKV in the third trimester had significantly higher levels of DENV, but not ZIKV, 240 IgG-NS1 than those exposed in the first trimester (Supplementary Figure 2A and B), reflecting 241 the decay of DENV-specific antibody levels in the latter. A similar trend was observed for the 242 children (Supplementary Figure 2C and D). These data also indicate different dynamics and/or 243 sources of DENV- and ZIKV-specific antibodies. Indeed, we did not observe a correlation between 244 ZIKV and DENV IgG-NS1 antibody levels in plasma from mothers (rho=-0.05; p=0.45) or 245 children (rho=0.004; p=0.95). These results are likely related to the modest effect of prior DENV 246 infections on the breadth and magnitude of ZIKV-reactive memory B cell responses [38]. In 247 summary, these findings confirm the passive transfer of maternal anti-orthoflavivirus IgG-NS1 248 249 (but not IgM-NS1) antibodies and their subsequent clearance around the sixth month after birth.

250

#### Poor association between ZIKV and DENV IgM-NS1 antibodies and CZS-related microcephaly

We next evaluated the relationship between ZIKV and DENV IgM-NS1 antibodies and the 253 development of microcephaly in children with CZS. Consistent with the low positivity rate in most 254 of the cases (Figure 2A and B: Supplementary Figure 1A), we did not observe significant 255 differences in ZIKV or DENV IgM-NS1 in the mothers of children with microcephaly versus those 256 without microcephaly, both in terms of the positivity rate (Figure 3A), or the relative plasma levels 257 (Figure 3B). In contrast, we observed that children with microcephaly exhibited a higher 258 seropositivity rate for ZIKV IgM-NS1 than those without microcephaly (Figure 3C). This 259 suggests a long-lasting IgM response in children with microcephaly, considering the early prenatal 260 exposure to ZIKV. However, the plasma levels of these antibodies (as well as those against DENV) 261 in general were below the detection limit (Figure 3D). Thus, overall, there is a minor association 262 263 between the IgM-NS1 response and the development of CZS-related microcephaly, and the ZIKV IgM-NS1 response is long-lasting in a fraction of the children. 264

265

# 266 Low pre-existing DENV IgG-NS1 is associated with CZS-related microcephaly

We examined the association between orthoflavivirus IgG-NS1 antibody levels in mothers and 267 children and the development of microcephaly. We observed that mothers of children with 268 microcephaly had a lower positivity rate for DENV IgG-NS1 in comparison with those without 269 microcephaly (Figure 4A). Of note, this comparison was not performed for ZIKV IgG-NS1 since 270 271 positivity for this test was a study inclusion criterion. When we evaluated the relative levels of IgG-NS1, we observed significantly lower levels of DENV, but not ZIKV, antibodies in mothers 272 273 of children with microcephaly relative to those without microcephaly (Figure 4B). In addition, we employed the DENV/ZIKV IgG-NS1 ratio to measure the predominant viral-specific humoral 274 response. This analysis indicated that mothers of children with microcephaly had a lower 275 DENV/ZIKV IgG-NS1 ratio in comparison with those without microcephaly (Figure 4C). 276 277 Interestingly, a ROC curve analysis indicated that the DENV/ZIKV IgG-NS1 ratio in samples from the mothers is robust in discriminating between both groups of children (Figure 4D). 278

#### 279

We also evaluated the association between IgG-NS1 in plasma from the children exposed 280 prenatally to ZIKV and the risk of microcephaly. Of note, the samples from children who 281 developed microcephaly were obtained at an older age (median [range] of 8.2 months [4-15]) than 282 those without microcephaly (median [range]: 6 months [1-19]; P=0.001). Thus, considering the 283 clearance of maternally-transferred antibodies beyond 6 months of age (Figures 2E and F) and 284 that passively transferred antibodies depended on maternal levels (Figure 2C and D), it was 285 286 expected observe that children with microcephaly had a lower positivity rate for DENV IgG-NS1 (Figure 4E), as well as lower relative levels of DENV-specific antibodies (Figure 4F), in 287 comparison with those without microcephaly. No differences were obtained for ZIKV IgG-NS1 288 antibodies (Figure 4E and F). The DENV/ZIKV IgG ratio analysis abrogates the bias introduced 289 by the difference in the age of children with and without microcephaly. We observed a significantly 290 lower DENV/ZIKV IgG-NS1 ratio in children with microcephaly in comparison with non-291 292 microcephalic children (Figure 4G), and this ratio could discriminate between both groups of children (Figure 4H). 293

294

Finally, we evaluated the levels of DENV and ZIKV IgM/IgG-NS1 in mothers and children 295 without microcephaly but who developed neurodevelopmental or ocular alterations and compared 296 them with those who did not develop CZS. Overall, we did not detect DENV and ZIKV IgM-NS1 297 in all the groups analyzed (Supplementary Figure 3A and C). Moreover, when we evaluated IgG-298 NS1, contrary to what we observed for microcephaly cases, we obtained comparable levels of 299 300 these antibodies in mothers of children with neurodevelopmental or ocular alterations relative to those without CZS (Supplementary Figure 3B). Mothers from children with neurodevelopmental 301 alterations had even significantly higher DENV IgG-NS1 antibodies than those from the no CZS 302 group (Supplementary Figure 3B). A similar non-significant trend was obtained in the children 303 (Supplementary Figure 3D). 304

In summary, low levels of pre-existing DENV IgG-NS1 antibodies are associated with the development of microcephaly, but not neurodevelopmental or ocular alterations, in children with CZS.

308

# 309 DISCUSSION

Developing safe and effective immunization strategies for women of reproductive age living in 310 orthoflavivirus endemic areas is a public health priority given the risks associated with the vertical 311 312 transmission of ZIKV [15]. In addition, identifying immune correlates of protection against CZS is highly needed. Here, we observed that pre-existing DENV IgG-NS1 antibodies in pregnant 313 women are placentally transferred to their children, and this passage depends on the maternal levels 314 of the antibodies. In addition, in the setting of ZIKV infection during pregnancy, higher levels of 315 these antibodies are associated with a reduced risk of CZS-related microcephaly but not with the 316 occurrence of neurodevelopmental or ocular alterations. In contrast, a minor association was 317 318 observed for the IgM-NS1 response, which is most likely explained by the absence of

transplacental passage of this isotype [35]. Consistent with these data, a previous study that prospectively followed a cohort of 1,453 adults in dengue-endemic areas demonstrated that a twofold increase in IgG titers against DENV NS1 is associated with a 9% reduction in the risk of ZIKV infection and symptoms [39]. Thus, pre-existing immunity directed to the NS1 protein of orthoflaviviruses seems to play a protective role against ZIKV infection and CZS-related microcephaly.

325

Due to its absence in viral particles, NS1 is usually not considered a vaccine target to induce 326 327 humoral responses against orthoflaviviruses. However, secreted and cell-associated forms of NS1 can be found, and both have varying immunogenic properties [18]. For instance, around 30% of 328 329 ZIKV- and DENV-reactive antibodies bind to NS1 [20,22]. Moreover, multiple studies have 330 shown a protective role of anti-NS1 against orthoflavivirus infection. As such, seminal work showed that immunization with DENV-2 NS1 confers protection against a homologous DENV 331 infection in mice [40]. More recent studies obtained similar findings in mice immunized with a 332 333 ZIKV NS1-based vaccine. Specifically, this vaccine elicited high titers of protective antibodies, and passive serum transfer from vaccinated mice conferred protection against lethal challenge [41]. 334 In addition, antibodies directed to the cell-surface form of ZIKV NS1 may confer protection 335 against ZIKV infection during pregnancy by a mechanism related to complement deposition and 336 337 opsonization [26]. Similarly, monoclonal antibodies directed to the cell-surface form of West Nile Virus NS1 activate Fcy receptor-mediated phagocytosis and clearance of infected cells [42], while 338 339 anti-ZIKV NS1 antibodies promote antibody-dependent cellular toxicity [43,44]. On the other hand, ZIKV NS1 induces placental dysfunction, increasing vascular permeability and spreading 340 the virus. Thus, anti-NS1 antibodies could also protect against ZIKV infection by decreasing the 341 immune evasion effects and placental dysfunction induced by the secreted form of NS1 [19,45]. 342

343

344 The previous studies indicate a protective role of anti-NS1 homotypic antibodies. However, it is unclear the role of anti-NS1 cross-reactive antibodies in individuals with pre-existing immunity to 345 DENV and subsequent ZIKV infection. In this regard, it is worth mentioning that the NS1 proteins 346 from DENV and ZIKV share some degree of homology [46,47], and some monoclonal antibodies 347 against DENV NS1 have cross-reactivity to ZIKV NS1 [48,49]. Importantly, these anti-DENV 348 NS1 cross-reactive antibodies can mediate protective effects against ZIKV NS1-induced 349 350 endothelial dysfunction [48], as well as decrease viral replication and cytokine production in vitro [49]. In contrast, other studies have shown that the depletion of DENV-reactive antibodies in 351 352 serum does not significantly affect ZIKV neutralization [38,50], suggesting that type-specific antibodies are responsible for most of this antibody-mediated protection. Considering the lack of 353 antibody-dependent enhancement of ZIKV infection by anti-NS1 antibodies [48], these studies 354 support the notion that cross-reactive antibodies targeting DENV NS1 may provide protection 355 356 against ZIKV infection and are a helpful vaccine target to prevent CZS.

357

In addition to the direct effects of anti-NS1 antibodies, they could be a surrogate of other immune mechanisms of protection against CZS. For instance, ZIKV NS1-based immunization in

immunocompetent mice was recently shown to elicit high levels of anti-ZIKV NS1 antibodies. 360 However, T cell-mediated immunity, rather than anti-NS1 antibodies, is crucial for protecting 361 against the ZIKV challenge in this model [51]. Alternatively, efficient cooperation between anti-362 363 DENV NS1 antibodies and CD4<sup>+</sup> T cells may be required for optimal protection upon NS1-based vaccination [52]. Moreover, the presence of antibodies to anti-ZIKV NS1 antibodies correlates 364 with the presence of ZIKV neutralizing antibodies, the latter probably being the direct protective 365 mechanism against infection [25]. In summary, anti-NS1 antibodies are an important arm of 366 humoral immunity against orthoflaviviruses. Their effector mechanisms and biological relevance 367 of homotypic and cross-reactive anti-NS1 antibodies in the setting of ZIKV infection and CZS 368 remain to be determined. 369

370

Several studies have documented neurodevelopment and ocular alterations in infants born to 371 mothers exposed to ZIKV during pregnancy, even in the absence of microcephaly [53,54]. 372 However, the mechanisms behind this clinical entity in the setting of ZIKV infection are unknown 373 374 [55]. Here, we show that these neurological alterations differ respective to microcephaly in CZS both in the time of ZIKV exposure and the association with placentally-transferred humoral 375 immunity. Likely, gestational ZIKV infection in the first trimester directly alters human brain cell 376 377 development [11], and low levels of protective anti-orthoflavivirus antibodies may predispose to microcephaly. However, ZIKV infection beyond this time (when macroscopic brain architecture 378 has been already developed), along with maternal immune activation upon infection (which could 379 380 be indicated by the levels of anti-NS1 antibodies), may lead to changes in functional brain connectivity and neurodevelopment alterations [56]. Novel studies should address the role of 381 maternal immune activation and orthoflavivirus humoral immunity in this setting. 382

383

Our study has some limitations. We did not prospectively measure antibody responses in pregnant 384 385 women early after ZIKV exposure, which could be better correlated with clinical outcomes in newborns. However, the results of our study with a high number of mothers/children binomials 386 387 exposed to prenatal ZIKV infection support the utility of measuring orthoflavivirus humoral immunity to identify individuals with increased risk of severe CZS in endemic areas. Furthermore, 388 it is important to note that children with microcephaly were older than those without this condition 389 at the time of sample analysis. This has implications for the levels of anti-NS1 antibodies. 390 391 However, the analysis of the DENV/ZIKV IgG-NS1 ratio (which is independent of the age of the child) is useful to control this variable between both groups of individuals. Finally, a limitation of 392 393 our study is that the mechanisms behind the association found for IgG-NS1 antibodies and 394 microcephaly development were not explored. In this regard, at least two unanswered questions remain to be addressed: which mechanisms are related to the association between anti-DENV NS1 395 antibodies and a good clinical outcome in CZS? Is the anti-NS1 IgG response a reflect of 396 397 homologous or heterologous neutralizing antibodies or virus-specific T cells playing a direct role in protection against ZIKV infection? 398

399

In conclusion, here we show that the development of microcephaly in children with CZS is associated with low plasma levels of placentally transferred, pre-existing DENV IgG-NS1 antibodies. These data align with the notion that the anti-orthoflavivirus NS1 IgG response may play a protective role against ZIKV infection during pregnancy. These results have important implications for the design of novel orthoflavivirus vaccine candidates and the identification of correlates of protection. As such, an optimal anti-orthoflavivirus NS1 IgG response may be required for adequate protection against prenatal ZIKV infection.

407

# 408 Acknowledgments

We thank the children and parents who kindly participated in this study and the Pediatric Department of Hospital Universitario de Neiva, particularly Elisabeth Días. We also thank the "Asociación Milagros de Dios" and Piedad Perilla for technical support.

412

# 413 **Funding information**

This study was supported by Universidad Surcolombiana, Vicerrectoría de Investigación grant code 3660, and the MIT International Science and Technology Initiatives (MISTI)-Colombia.

416

#### 417 **REFERENCES**

- Gutiérrez-Bugallo G, Piedra LA, Rodriguez M, Bisset JA, Lourenço-de-Oliveira R, Weaver SC, et al.
   Vector-borne transmission and evolution of Zika virus. Nat Ecol Evol. 2019;3: 561–569.
   doi:10.1038/s41559-019-0836-z
- Hasan SS, Sevvana M, Kuhn RJ, Rossmann MG. Structural biology of Zika virus and other
   flaviviruses. Nat Struct Mol Biol. 2018;25: 13–20. doi:10.1038/s41594-017-0010-8
- 423 3. WHO. Zika Virus. 2022 [cited 29 Apr 2024]. Available: https://www.who.int/news-room/fact424 sheets/detail/zika-virus
- Pacheco O, Beltrán M, Nelson CA, Valencia D, Tolosa N, Farr SL, et al. Zika Virus Disease in
   Colombia Preliminary Report. N Engl J Med. 2020;383: e44. doi:10.1056/NEJMoa1604037
- 427 5. European Centre for Disease Prevention and Control. Rapid risk assessment: Microcephaly in
  428 Brazil potentially linked to the Zika virus epidemic, 25 November 2015. 2015. Available:
  429 https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-microcephaly-brazil430 potentially-linked-zika-virus-epidemic
- 431 6. Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical syndromes. Nature.
   432 2018;560: 573–581. doi:10.1038/s41586-018-0446-y

Freitas DA, Souza-Santos R, Carvalho LMA, Barros WB, Neves LM, Brasil P, et al. Congenital Zika
syndrome: A systematic review. PLoS One. 2020;15: e0242367-. Available:
https://doi.org/10.1371/journal.pone.0242367

- N Costa MC, Cardim LL, Teixeira MG, Barreto ML, Carvalho-Sauer R de CO de, Barreto FR, et al.
   Case Fatality Rate Related to Microcephaly Congenital Zika Syndrome and Associated Factors: A
   Nationwide Retrospective Study in Brazil <sup>+</sup>. Viruses. 2020;12. doi:10.3390/v12111228
- 439 9. Cuevas EL, Tong VT, Rozo N, Valencia D, Pacheco O, Gilboa SM, et al. Preliminary Report of
  440 Microcephaly Potentially Associated with Zika Virus Infection During Pregnancy Colombia,
  441 January–November 2016. MMWR Morb Mortal Wkly Rep. 2016. doi:10.15585/mmwr.mm6549e1
- 44210.Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika virus infects human cortical neural443progenitors and attenuates their growth. Cell Stem Cell. 2016. doi:10.1016/j.stem.2016.02.016
- Garcez PP, Loiola EC, Madeiro da Costa R, Higa LM, Trindade P, Delvecchio R, et al. Zika virus
  impairs growth in human neurospheres and brain organoids. Science (1979). 2016;352: 816–818.
  doi:10.1126/science.aaf6116
- 12. Naveca FG, Pontes GS, Chang AY-H, Silva GAV da, Nascimento VA do, Monteiro DC da S, et al.
  Analysis of the immunological biomarker profile during acute Zika virus infection reveals the
  overexpression of CXCL10, a chemokine linked to neuronal damage. Mem Inst Oswaldo Cruz.
  2018;113: e170542. doi:10.1590/0074-02760170542
- 451 13. Ornelas AMM, Pezzuto P, Silveira PP, Melo FO, Ferreira TA, Oliveira-Szejnfeld PS, et al. Immune
  452 activation in amniotic fluid from Zika virus-associated microcephaly. Ann Neurol. 2017;81: 152–
  453 156. doi:10.1002/ana.24839
- 454 14. Lum F-M, Low DKS, Fan Y, Tan JJL, Lee B, Chan JKY, et al. Zika Virus Infects Human Fetal Brain
  455 Microglia and Induces Inflammation. Clin Infect Dis. 2017;64: 914–920. doi:10.1093/cid/ciw878
- Priyamvada L, Suthar MS, Ahmed R, Wrammert J. Humoral Immune Responses Against Zika Virus
  Infection and the Importance of Preexisting Flavivirus Immunity. J Infect Dis. 2017;216: S906–
  S911. doi:10.1093/infdis/jix513
- 459 16. Sapparapu G, Fernandez E, Kose N, Cao B, Fox JM, Bombardi RG, et al. Neutralizing human
  460 antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540: 443–447.
  461 doi:10.1038/nature20564
- 462 17. Rathore APS, Saron WAA, Lim T, Jahan N, St. John AL. Maternal immunity and antibodies to
  463 dengue virus promote infection and Zika virus–induced microcephaly in fetuses. Sci Adv. 2019.
  464 doi:10.1126/sciadv.aav3208

Muller DA, Young PR. The flavivirus NS1 protein: molecular and structural biology, immunology,
role in pathogenesis and application as a diagnostic biomarker. Antiviral Res. 2013;98: 192–208.
doi:10.1016/j.antiviral.2013.03.008

- 468 19. Puerta-Guardo H, Tabata T, Petitt M, Dimitrova M, Glasner DR, Pereira L, et al. Zika Virus
  469 Nonstructural Protein 1 Disrupts Glycosaminoglycans and Causes Permeability in Developing
  470 Human Placentas. J Infect Dis. 2020;221: 313–324. doi:10.1093/infdis/jiz331
- 471 20. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross472 reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353: 823–826.
  473 doi:10.1126/science.aaf8505
- 474 21. Cavazzoni CB, Bozza VBT, Lucas TC V, Conde L, Maia B, Mesin L, et al. The immunodominant
  475 antibody response to Zika virus NS1 protein is characterized by cross-reactivity to self. J Exp
  476 Med. 2021;218. doi:10.1084/jem.20210580
- 477 22. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al.
  478 Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328: 745–
  479 748. doi:10.1126/science.1185181
- 480 23. Fisher R, Lustig Y, Sklan EH, Schwartz E. The Role of NS1 Protein in the Diagnosis of Flavivirus
  481 Infections. Viruses. 2023;15. doi:10.3390/v15020572
- 482 24. Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, et al. Human antibodies targeting
  483 Zika virus NS1 provide protection against disease in a mouse model. Nat Commun. 2018;9: 4560.
  484 doi:10.1038/s41467-018-07008-0
- Sornjai W, Ramphan S, Wikan N, Auewarakul P, Smith DR. High correlation between Zika virus
  NS1 antibodies and neutralizing antibodies in selected serum samples from normal healthy Thais.
  Sci Rep. 2019;9: 13498. doi:10.1038/s41598-019-49569-0
- Wessel AW, Kose N, Bombardi RG, Roy V, Chantima W, Mongkolsapaya J, et al. Antibodies
  targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during
  pregnancy. Nat Commun. 2020;11: 5278. doi:10.1038/s41467-020-19096-y
- 491 27. Badolato-Corrêa J, Carvalho FR, Paiva IA, Familiar-Macedo D, Dias HG, Pauvolid-Corrêa A, et al.
  492 Differential Longevity of Memory CD4 and CD8 T Cells in a Cohort of the Mothers With a History
  493 of ZIKV Infection and Their Children. Front Immunol. 2021;12: 610456.
  494 doi:10.3389/fimmu.2021.610456
- 495 28. Fialho EMS, Veras EM, Jesus CM de, Gomes LN, Khouri R, Sousa PS, et al. Maternal Th17 Profile
  496 after Zika Virus Infection Is Involved in Congenital Zika Syndrome Development in Children.
  497 Viruses. 2023;15. doi:10.3390/v15061320

498 Gutierrez-Barbosa H, Medina-Moreno S, Zapata JC, Chua J V. Dengue Infections in Colombia: 29. 499 Epidemiological Trends of a Hyperendemic Country. Trop Med Infect Dis. 2020;5. 500 doi:10.3390/tropicalmed5040156 501 30. Visser L, Ruiter SAJ, Van der Meulen BF, Ruijssenaars WAJJM, Timmerman ME. Validity and 502 suitability of the Bayley-III Low Motor/Vision version: a comparative study among young children 503 with and without motor and/or visual impairments. Res Dev Disabil. 2013;34: 3736–3745. 504 doi:10.1016/j.ridd.2013.07.027 Mejia-Wimar R, Veloza M, Rodríguez-Rodríguez J, Narváez C, Vega R, Salgado D, et al. 505 31. 506 Neurodevelopmental follow-up of children with prenatal exposure to Zika virus. Revista 507 Mexicana de Pediatría. 2022;89: 246-253. doi:10.35366/111690 508 32. Salgado DM, Vega R, Rodríguez JA, Niño Á, Rodríguez R, Ortiz Á, et al. Clinical, laboratory and 509 immune aspects of Zika virus-associated encephalitis in children. Int J Infect Dis. 2020;90: 104– 110. doi:10.1016/j.ijid.2019.10.030 510 511 33. Castro-Trujillo S, Segura K, Bolívar-Marín S, Salgado DM, Bosch I, Vega R, et al. NS1-Specific 512 Antibody Response Facilitates the Identification of Children With Dengue and Zika in Hyperendemic Areas. Pediatr Infect Dis J. 2024;43. 513 514 34. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective 515 516 study. The Lancet. 2016;387: 2125–2132. doi:https://doi.org/10.1016/S0140-6736(16)00651-6 517 35. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012: 985646. 518 doi:10.1155/2012/985646 519 520 Castanha PMS, Braga C, Cordeiro MT, Souza AI, Silva CDJ, Martelli CMT, et al. Placental Transfer 36. 521 of Dengue Virus (DENV)-Specific Antibodies and Kinetics of DENV Infection-Enhancing Activity in 522 Brazilian Infants. J Infect Dis. 2016;214: 265–272. doi:10.1093/infdis/jiw143 523 Singh T, Lopez CA, Giuberti C, Dennis ML, Itell HL, Heimsath HJ, et al. Efficient transplacental IgG 37. transfer in women infected with Zika virus during pregnancy. PLoS Negl Trop Dis. 2019;13: 524 525 e0007648. doi:10.1371/journal.pntd.0007648 526 38. Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cárdenas M, Katzelnick LC, et al. Impact of 527 pre-existing dengue immunity on human antibody and memory B cell responses to Zika. Nat Commun. 2019. doi:10.1038/s41467-019-08845-3 528 529 39. Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery NJ, Castanha PMS, Sacramento GA, et al. 530 Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science. 2019;363: 607–610. doi:10.1126/science.aav6618 531

53240.Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by533immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol. 1987;68 (Pt5343): 853–857. doi:10.1099/0022-1317-68-3-853

- 53541.Bailey MJ, Broecker F, Duehr J, Arumemi F, Krammer F, Palese P, et al. Antibodies Elicited by an536NS1-Based Vaccine Protect Mice against Zika Virus. mBio. 2019;10. doi:10.1128/mBio.02861-18
- 537 42. Chung KM, Thompson BS, Fremont DH, Diamond MS. Antibody recognition of cell surface538 associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile
  539 Virus-infected cells. J Virol. 2007;81: 9551–9555. doi:10.1128/JVI.00879-07
- Sanchez Vargas LA, Adam A, Masterson M, Smith M, Lyski ZL, Dowd KA, et al. Non-structural
  protein 1-specific antibodies directed against Zika virus in humans mediate antibody-dependent
  cellular cytotoxicity. Immunology. 2021;164: 386–397. doi:10.1111/imm.13380
- Lei Y, Xinglong L, Xianmiao Y, Wan S, Xiaoyan Z, Weiqi D, et al. Monoclonal Antibodies against
  Zika Virus NS1 Protein Confer Protection via Fcγ Receptor-Dependent and -Independent
  Pathways. mBio. 2021;12: 10.1128/mbio.03179-20. doi:10.1128/mbio.03179-20
- 45. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1
  triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci
  Transl Med. 2015;7: 304ra141-304ra141. doi:10.1126/scitranslmed.aaa3787
- 549 46. Chang H-H, Huber RG, Bond PJ, Grad YH, Camerini D, Maurer-Stroh S, et al. Systematic analysis of
  550 protein identity between Zika virus and other arthropod-borne viruses. Bull World Health Organ.
  551 2017;95: 517-525I. doi:10.2471/BLT.16.182105
- 47. Wen J, Shresta S. Antigenic cross-reactivity between Zika and dengue viruses: is it time to
  develop a universal vaccine? Curr Opin Immunol. 2019;59: 1–8.
  doi:https://doi.org/10.1016/j.coi.2019.02.001
- Biering SB, Akey DL, Wong MP, Brown WC, Lo NTN, Puerta-Guardo H, et al. Structural basis for
  antibody inhibition of flavivirus NS1-triggered endothelial dysfunction. Science. 2021;371: 194–
  200. doi:10.1126/science.abc0476
- Sootichote R, Puangmanee W, Benjathummarak S, Kowaboot S, Yamanaka A, Boonnak K, et al.
  Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and
  Zika Virus Infections. Biomedicines. 2023;11. doi:10.3390/biomedicines11010227
- 561 50. Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, et al. Lack of Durable Cross562 Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis.
  563 2017;23: 773–781. doi:10.3201/eid2305.161630

564 565 566	51.	Grubor-Bauk B, Wijesundara DK, Masavuli M, Abbink P, Peterson RL, Prow NA, et al. NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice. Sci Adv. 2019;5: eaax2388. doi:10.1126/sciadv.aax2388
567 568 569 570	52.	Gonçalves AJS, Oliveira ERA, Costa SM, Paes M V, Silva JFA, Azevedo AS, et al. Cooperation between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a DNA Vaccine Based on the NS1 Antigen. PLoS Negl Trop Dis. 2015;9: e0004277 Available: https://doi.org/10.1371/journal.pntd.0004277
571 572 573 574 575	53.	Tiene SF, Cranston JS, Nielsen-Saines K, Kerin T, Fuller T, Vasconcelos Z, et al. Early Predictors of Poor Neurologic Outcomes in a Prospective Cohort of Infants With Antenatal Exposure to Zika Virus. Pediatr Infect Dis J. 2022;41. Available: https://journals.lww.com/pidj/fulltext/2022/03000/early_predictors_of_poor_neurologic_outco mes_in_a.24.aspx
576 577 578 579	54.	Einspieler C, Utsch F, Brasil P, Panvequio Aizawa CY, Peyton C, Hydee Hasue R, et al. Association of Infants Exposed to Prenatal Zika Virus Infection With Their Clinical, Neurologic, and Developmental Status Evaluated via the General Movement Assessment Tool. JAMA Netw Open. 2019;2: e187235–e187235. doi:10.1001/jamanetworkopen.2018.7235
580 581 582 583	55.	Schuler-Faccini L, del Campo M, García-Alix A, Ventura LO, Boquett JA, van der Linden V, et al. Neurodevelopment in Children Exposed to Zika in utero: Clinical and Molecular Aspects. Front Genet. 2022;13. Available: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.758715
584 585 586 587	56.	Spann MN, Monk C, Scheinost D, Peterson BS. Maternal Immune Activation During the Third Trimester Is Associated with Neonatal Functional Connectivity of the Salience Network and Fetal to Toddler Behavior. The Journal of Neuroscience. 2018;38: 2877. doi:10.1523/JNEUROSCI.2272- 17.2018
588		
589		
590		
591		
592		
593		
594		
595		

220
-----

#### **FIGURE LEGENDS**

**Figure 1. Study flowchart**. <sup>1</sup>The plasma sample was taken after birth in the clinical follow-up.

597 598

> **Figure 2. Placentally-transferred IgG-NS1. A-B.** Correlation analysis of the relative plasma levels of ZIKV (A) and DENV1-4 (B) IgM-NS1 between mothers and children. **C-D.** Correlation analysis of the relative levels of ZIKV (**C**) and DENV1-4 (**D**) IgG-NS1 between mothers and children. **E-F.** Correlation and non-linear regression analysis of the relative levels of ZIKV (**E**) and DENV1-4 (**F**) IgG-NS1 in relation to the children age. In all the cases, the *rho* and p-value of the Spearman test are shown. The dashed lines indicate the ELISA limit of detection.

605

606 Figure 3. Poor association between IgM-NS1 antibodies and CZS-related microcephaly. A

and C. Frequency of ZIKV and DENV1-4 IgM-NS1 positivity rate in mothers (A) and children

608 (C) with or without microcephaly; Fisher's test. **B** and **D**. Relative levels of ZIKV and DENV1-4

IgM-NS1 in mothers (**B**) and children (**D**) with or without microcephaly; Mann-Whitney test. The dashed lines indicate the ELISA limit of detection. NS: Not statistically significant. \*p<0.05.

611

Figure 4. Association between IgG-NS1 antibodies and CZS-related microcephaly. A. 612 Frequency of DENV1-4 IgG-NS1 positivity rate in mothers of children with or without 613 microcephaly. **B.** Relative plasma levels of ZIKV and DENV1-4 IgG-NS1 in mothers of children 614 with or without microcephaly. C-D. DENV1-4/ZIKV IgG-NS1 ratio in mothers of children with 615 or without microcephaly (C), and the respective ROC curve analysis (D). E. Frequency of ZIKV 616 and DENV1-4 IgG-NS1 positivity rate in children with or without microcephaly. F. Relative 617 plasma levels of ZIKV and DENV1-4 IgG-NS1 in children with or without microcephaly. G-H. 618 619 DENV1-4/ZIKV IgG-NS1 ratio in children with or without microcephaly (G), and the respective ROC curve analysis (H). In A and E, the p-value of the Fisher's test is shown. In B, C, F, and G, 620 the p-value of the Mann-Whitney test is shown. The dashed lines indicate the ELISA limit of 621 detection. NS: Not statistically significant. \*\*p<0.01; \*\*\*p<0.001. 622

623

Supplementary Figure 1. Comparison of the relative plasma levels of ZIKV and DENV1-4 IgMNS1 (A) and IgG-NS1 (B) in mothers and children. In all the cases, the positivity rate (PR) and
the p-value of the Mann-Whitney test are shown. The dashed lines indicate the ELISA limit of
detection. \*\*\*p<0.001.</li>

628

**Supplementary Figure 2.** Comparison of the relative plasma levels of ZIKV (**A** and **C**) and DENV1-4 (**B** and **D**) IgG-NS1 in mothers (**A** and **B**) and children (**C** and **D**) after gestational ZIKV exposure during the first or the third trimesters. In all the cases, the p-value of the Mann-Whitney test is shown. The dashed lines indicate the ELISA limit of detection. NS: Not statistically significant. \*\*p<0.01

634

Supplementary Figure 3. Comparison of the relative plasma levels of ZIKV and DENV1-4 IgMNS1 (A and C) and IgG-NS1 (B and D) in mothers (A and B) and children (C and D) without
CZS, or those with neurodevelopment and ocular alterations. The p-value of Dunn's test is shown.

638 The dashed lines indicate the ELISA limit of detection. NS: Not statistically significant. 639 \*\*\*P<0.001 IgM-NS1 Orthoflavivirus (OD 450 nm)







Mothers
 Children



Mother IgG-NS1 Orthoflavivirus



Figure 4

Mothers and children with clinical suspicion of prenatal ZIKV exposure during ZIKV epidemic (June 2015 - October 2016) in Huila-Colombia

N= 436



# Figure 1

Mothers IgM-NS1 Orthoflavivirus



# Children IgM-NS1 Orthoflavivirus



Figure 3